Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by LPL Financial LLC

LPL Financial LLC grew its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 33.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,036 shares of the medical device company’s stock after buying an additional 12,099 shares during the period. LPL Financial LLC owned 0.07% of Tandem Diabetes Care worth $1,730,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. AlphaQuest LLC boosted its holdings in shares of Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 541 shares in the last quarter. Jones Financial Companies Lllp increased its stake in shares of Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock worth $41,000 after purchasing an additional 748 shares in the last quarter. McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care in the third quarter worth $52,000. Assetmark Inc. lifted its holdings in Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 535 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock worth $65,000 after acquiring an additional 1,101 shares during the last quarter.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock opened at $17.26 on Thursday. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The stock has a 50 day moving average of $22.47 and a 200-day moving average of $30.46. The stock has a market cap of $1.15 billion, a P/E ratio of -8.94 and a beta of 1.52. Tandem Diabetes Care, Inc. has a 52 week low of $15.75 and a 52 week high of $53.69.

Insider Transactions at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos purchased 10,538 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TNDM. Robert W. Baird dropped their target price on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Citigroup lowered shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and decreased their price target for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Barclays dropped their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $22.00 target price (down previously from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Nine equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.88.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.